{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:41:18Z","timestamp":1792734078286,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:00:00Z","timestamp":1382054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:00:00Z","timestamp":1382054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Spinal muscular atrophy (SMA) is a neuromuscular disease resulting from mutations in the <jats:italic>survival motor neuron 1<\/jats:italic> (<jats:italic>SMN1<\/jats:italic>) gene. Recent breakthroughs in preclinical research have highlighted several potential novel therapies for SMA, increasing the need for robust and sensitive clinical trial platforms for evaluating their effectiveness in human patient cohorts. Given that most clinical trials for SMA are likely to involve young children, there is a need for validated molecular biomarkers to assist with monitoring disease progression and establishing the effectiveness of therapies being tested. Proteomics technologies have recently been highlighted as a potentially powerful tool for such biomarker discovery.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We utilized label-free proteomics to identify individual proteins in pathologically-affected skeletal muscle from SMA mice that report directly on disease status. Quantitative fluorescent western blotting was then used to assess whether protein biomarkers were robustly changed in muscle, skin and blood from another mouse model of SMA, as well as in a small cohort of human SMA patient muscle biopsies.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>By comparing the protein composition of skeletal muscle in SMA mice at a pre-symptomatic time-point with the muscle proteome at a late-symptomatic time-point we identified increased expression of both Calreticulin and GRP75\/Mortalin as robust indicators of disease progression in SMA mice. We report that these protein biomarkers were consistently modified in different mouse models of SMA, as well as across multiple skeletal muscles, and were also measurable in skin biopsies. Furthermore, Calreticulin and GRP75\/Mortalin were measurable in muscle biopsy samples from human SMA patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>We conclude that label-free proteomics technology provides a powerful platform for biomarker identification in SMA, revealing Calreticulin and GRP75\/Mortalin as peripherally accessible protein biomarkers capable of reporting on disease progression in samples of muscle and skin.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/gm498","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T03:01:42Z","timestamp":1382065302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Label-free proteomics identifies Calreticulin and GRP75\/Mortalin as peripherally accessible protein biomarkers for spinal muscular atrophy"],"prefix":"10.1186","volume":"5","author":[{"given":"Chantal A","family":"Mutsaers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J","family":"Lamont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Wishart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H","family":"Gillingwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,18]]},"reference":[{"key":"489_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M: Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995, 80: 155-165.","journal-title":"Cell"},{"key":"489_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AH Burghes","year":"2009","unstructured":"Burghes AH, Beattie CE: Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nat Rev Neurosci. 2009, 10: 597-609.","journal-title":"Nat Rev Neurosci"},{"key":"489_CR3","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1093\/hmg\/ddq147","volume":"19","author":"CL Lorson","year":"2010","unstructured":"Lorson CL, Rindt H, Shababi M: Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum Mol Genet. 2010, 19: R111-R118.","journal-title":"Hum Mol Genet"},{"key":"489_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton G, Gillingwater TH: Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013, 19: 40-50.","journal-title":"Trends Mol Med"},{"key":"489_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/hmg\/ddm367","volume":"17","author":"LM Murray","year":"2008","unstructured":"Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH: Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet. 2008, 17: 949-962.","journal-title":"Hum Mol Genet"},{"key":"489_CR6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH: Spinal muscular atrophy. Lancet. 2008, 371: 2120-2133.","journal-title":"Lancet"},{"key":"489_CR7","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1093\/hmg\/ddr360","volume":"20","author":"CA Mutsaers","year":"2011","unstructured":"Mutsaers CA, Wishart TM, Lamont DJ, Riessland M, Schreml J, Comley LH, Murray LM, Parson SH, Lochmuller H, Wirth B, Talbot K, Gillingwater TH: Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Hum Mol Genet. 2011, 20: 4334-4344.","journal-title":"Hum Mol Genet"},{"key":"489_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/hmg\/ddr453","volume":"21","author":"KK Ling","year":"2012","unstructured":"Ling KK, Gibbs RM, Feng Z, Ko CP: Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2012, 21: 185-195.","journal-title":"Hum Mol Genet"},{"key":"489_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","volume":"57","author":"KJ Swoboda","year":"2005","unstructured":"Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB: Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005, 57: 704-712.","journal-title":"Ann Neurol"},{"key":"489_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea GE, Krober S, McWhorter ML, Rossoll W, Muller S, Krawczak M, Bassell GJ, Beattie CE, Wirth B: Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008, 320: 524-527.","journal-title":"Science"},{"key":"489_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010, 28: 271-274.","journal-title":"Nat Biotechnol"},{"key":"489_CR12","doi-asserted-by":"publisher","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, Azzouz M: Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010, 2: 35ra42-","journal-title":"Sci Transl Med"},{"key":"489_CR13","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1093\/hmg\/ddq300","volume":"19","author":"AK Bevan","year":"2010","unstructured":"Bevan AK, Hutchinson KR, Foust KD, Braun L, McGovern VL, Schmelzer L, Ward JG, Petruska JC, Lucchesi PA, Burghes AH, Kaspar BK: Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet. 2010, 19: 3895-3905.","journal-title":"Hum Mol Genet"},{"key":"489_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/hmg\/ddq514","volume":"20","author":"E Dominguez","year":"2011","unstructured":"Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, Carcenac R, Astord S, Pereira de Moura A, Voit T, Barkats M: Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2011, 20: 681-693.","journal-title":"Hum Mol Genet"},{"key":"489_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.nurt.2008.08.007","volume":"5","author":"M Oskoui","year":"2008","unstructured":"Oskoui M, Kaufmann P: Spinal muscular atrophy. Neurotherapeutics. 2008, 5: 499-506.","journal-title":"Neurotherapeutics"},{"key":"489_CR16","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","volume":"12","author":"L Brichta","year":"2003","unstructured":"Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003, 12: 2481-2489.","journal-title":"Hum Mol Genet"},{"key":"489_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1021\/jm061475p","volume":"51","author":"J Thurmond","year":"2008","unstructured":"Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M, Andresson T, Bragason G, Thosteinsdottir M, Bjornsson JM, Coovert DD, Burghes AH, Gurney ME, Singh J: Synthesis and biological evaluation of novel 2, 4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J Med Chem. 2008, 51: 449-469.","journal-title":"J Med Chem"},{"key":"489_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0883073807305665","volume":"22","author":"KJ Swoboda","year":"2007","unstructured":"Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D\u2019Anjou G, Krosschell KJ, Reyna SP, Schroth MK, Scott CB, Simard LR: Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. 2007, 22: 957-966.","journal-title":"J Child Neurol"},{"key":"489_CR19","doi-asserted-by":"publisher","first-page":"e60113","DOI":"10.1371\/journal.pone.0060113","volume":"8","author":"DT Kobayashi","year":"2013","unstructured":"Kobayashi DT, Shi J, Stephen L, Ballard KL, Dewey R, Mapes J, Chung B, McCarthy K, Swoboda KJ, Crawford TO, Li R, Plasterer T, Joyce C, Chung WK, Kaufmann P, Darras BT, Finkel RS, Sproule DM, Martens WB, McDermott MP, De Vivo DC, Walker MG, Chen KS: SMA-MAP: a plasma protein panel for spinal muscular atrophy. PLoS One. 2013, 8: e60113-","journal-title":"PLoS One"},{"key":"489_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/gm421","volume":"5","author":"PC Guest","year":"2013","unstructured":"Guest PC, Gottschalk MG, Bahn S: Proteomics: improving biomarker translation to modern medicine?. Genome Med. 2013, 5: 17-","journal-title":"Genome Med"},{"key":"489_CR21","doi-asserted-by":"publisher","first-page":"e35462","DOI":"10.1371\/journal.pone.0035462","volume":"7","author":"RS Finkel","year":"2012","unstructured":"Finkel RS, Crawford TO, Swoboda KJ, Kaufmann P, Juhasz P, Li X, Guo Y, Li RH, Trachtenberg F, Forrest SJ, Kobayashi DT, Chen KS, Joyce CL, Plasterer T: Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study. PLoS One. 2012, 7: e35462-","journal-title":"PLoS One"},{"key":"489_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jneumeth.2012.06.020","volume":"209","author":"BF El-Khodor","year":"2012","unstructured":"El-Khodor BF, Cirillo K, Beltran JA, Mushlin R, Winberg ML, Charney R, Chomicova O, Marino T, Ramboz S: Prediction of death in the SMNDelta7 mouse model of spinal muscular atrophy: insight into disease stage and progression. J Neurosci Methods. 2012, 209: 259-268.","journal-title":"J Neurosci Methods"},{"key":"489_CR23","doi-asserted-by":"publisher","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","volume":"7","author":"TO Crawford","year":"2012","unstructured":"Crawford TO, Paushkin SV, Kobayashi DT, Forrest SJ, Joyce CL, Finkel RS, Kaufmann P, Swoboda KJ, Tiziano D, Lomastro R, Li RH, Trachtenberg FL, Plasterer T, Chen KS: Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One. 2012, 7: e33572-","journal-title":"PLoS One"},{"key":"489_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","volume":"9","author":"UR Monani","year":"2000","unstructured":"Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, Jablonka S, Schrank B, Rossoll W, Prior TW, Morris GE, Burghes AH: The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-\/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000, 9: 333-339.","journal-title":"Hum Mol Genet"},{"key":"489_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","volume":"24","author":"HM Hsieh-Li","year":"2000","unstructured":"Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H: A mouse model for spinal muscular atrophy. Nat Genet. 2000, 24: 66-70.","journal-title":"Nat Genet"},{"key":"489_CR26","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","volume":"19","author":"M Riessland","year":"2010","unstructured":"Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B: SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet. 2010, 19: 1492-1506.","journal-title":"Hum Mol Genet"},{"key":"489_CR27","unstructured":"EuroBioBank.http:\/\/www.eurobiobank.org\/,"},{"key":"489_CR28","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.nmd.2010.06.013","volume":"20","author":"LM Murray","year":"2010","unstructured":"Murray LM, Gillingwater TH, Parson SH: Using mouse cranial muscles to investigate neuromuscular pathology in vivo. Neuromuscular Disord. 2010, 20: 740-743. 10.1016\/j.nmd.2010.06.013.","journal-title":"Neuromuscular Disord"},{"key":"489_CR29","doi-asserted-by":"publisher","first-page":"e1002936","DOI":"10.1371\/journal.pgen.1002936","volume":"8","author":"TM Wishart","year":"2012","unstructured":"Wishart TM, Rooney TM, Lamont DJ, Wright AK, Morton AJ, Jackson M, Freeman MR, Gillingwater TH: Combining comparative proteomics and molecular genetics uncovers regulators of synaptic and axonal stability and degeneration in vivo. PLoS Genet. 2012, 8: e1002936-","journal-title":"PLoS Genet"},{"key":"489_CR30","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1093\/hmg\/ddq340","volume":"19","author":"TM Wishart","year":"2010","unstructured":"Wishart TM, Huang JP, Murray LM, Lamont DJ, Mutsaers CA, Ross J, Geldsetzer P, Ansorge O, Talbot K, Parson SH, Gillingwater TH: SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet. 2010, 19: 4216-4228.","journal-title":"Hum Mol Genet"},{"key":"489_CR31","unstructured":"ProteomeXchange.http:\/\/proteomecentral.proteomexchange.org,"},{"key":"489_CR32","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1074\/mcp.M600457-MCP200","volume":"6","author":"TM Wishart","year":"2007","unstructured":"Wishart TM, Paterson JM, Short DM, Meredith S, Robertson KA, Sutherland C, Cousin MA, Dutia MB, Gillingwater TH: Differential proteomics analysis of synaptic proteins identifies potential cellular targets and protein mediators of synaptic neuroprotection conferred by the slow Wallerian degeneration (Wlds) gene. Mol Cell Proteomics. 2007, 6: 1318-1330.","journal-title":"Mol Cell Proteomics"},{"key":"489_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/hmg\/ddp506","volume":"19","author":"LM Murray","year":"2010","unstructured":"Murray LM, Lee S, Baumer D, Parson SH, Talbot K, Gillingwater TH: Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Hum Mol Genet. 2010, 19: 420-433.","journal-title":"Hum Mol Genet"},{"key":"489_CR34","unstructured":"BioGPS.http:\/\/www.biogps.org,"},{"key":"489_CR35","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1021\/pr1005263","volume":"9","author":"HR Fuller","year":"2010","unstructured":"Fuller HR, Man NT, le Lam T, Shamanin VA, Androphy EJ, Morris GE: Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells. J Proteome Res. 2010, 9: 4228-4233.","journal-title":"J Proteome Res"},{"key":"489_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2202-12-25","volume":"12","author":"CY Wu","year":"2011","unstructured":"Wu CY, Whye D, Glazewski L, Choe L, Kerr D, Lee KH, Mason RW, Wang W: Proteomic assessment of a cell model of spinal muscular atrophy. BMC Neurosci. 2011, 12: 25-","journal-title":"BMC Neurosci"},{"key":"489_CR37","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10875-013-9885-2","volume":"33","author":"M Ni","year":"2013","unstructured":"Ni M, Wei W, Wang Y, Zhang N, Ding H, Shen C, Zheng F: Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis. J Clin Immunol. 2013, 33: 947-953.","journal-title":"J Clin Immunol"},{"key":"489_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.molonc.2009.11.003","volume":"4","author":"P Gromov","year":"2010","unstructured":"Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE: Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol. 2010, 4: 65-89.","journal-title":"Mol Oncol"},{"key":"489_CR39","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s12272-012-1018-6","volume":"35","author":"MN Song","year":"2012","unstructured":"Song MN, Moon PG, Lee JE, Na M, Kang W, Chae YS, Park JY, Park H, Baek MC: Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS\/MS. Arch Pharm Res. 2012, 35: 1839-1847.","journal-title":"Arch Pharm Res"},{"key":"489_CR40","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1245\/s10434-008-0243-1","volume":"16","author":"CN Chen","year":"2009","unstructured":"Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM, Ho MC, Hsieh FJ, Lee PH, Kuo ML, Lee H, Chang KJ: Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol. 2009, 16: 524-533.","journal-title":"Ann Surg Oncol"},{"key":"489_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00262-011-1146-8","volume":"61","author":"R Liu","year":"2012","unstructured":"Liu R, Gong J, Chen J, Li Q, Song C, Zhang J, Li Y, Liu Z, Dong Y, Chen L, Jin B: Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother. 2012, 61: 855-864.","journal-title":"Cancer Immunol Immunother"},{"key":"489_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/annonc\/mdi062","volume":"16","author":"WM Hsu","year":"2005","unstructured":"Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Chen CN, Lai DM, Hsieh LJ, Wang BT, Tsao PN, Lee H, Lin MT, Lai HS, Chen WJ: Calreticulin expression in neuroblastoma\u2013a novel independent prognostic factor. Ann Oncol. 2005, 16: 314-321.","journal-title":"Ann Oncol"},{"key":"489_CR43","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1523\/JNEUROSCI.5431-11.2012","volume":"32","author":"N Bernard-Marissal","year":"2012","unstructured":"Bernard-Marissal N, Moumen A, Sunyach C, Pellegrino C, Dudley K, Henderson CE, Raoul C, Pettmann B: Reduced calreticulin levels link endoplasmic reticulum stress and Fas-triggered cell death in motoneurons vulnerable to ALS. J Neurosci. 2012, 32: 4901-4912.","journal-title":"J Neurosci"},{"key":"489_CR44","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1074\/jbc.270.4.1705","volume":"270","author":"T Bhattacharyya","year":"1995","unstructured":"Bhattacharyya T, Karnezis AN, Murphy SP, Hoang T, Freeman BC, Phillips B, Morimoto RI: Cloning and subcellular localization of human mitochondrial hsp70. J Biol Chem. 1995, 270: 1705-1710.","journal-title":"J Biol Chem"},{"key":"489_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1042\/bj3110119","volume":"311","author":"OI Ornatsky","year":"1995","unstructured":"Ornatsky OI, Connor MK, Hood DA: Expression of stress proteins and mitochondrial chaperonins in chronically stimulated skeletal muscle. Biochem J. 1995, 311: 119-123.","journal-title":"Biochem J"},{"key":"489_CR46","doi-asserted-by":"crossref","first-page":"C1380","DOI":"10.1152\/ajpcell.1998.274.5.C1380","volume":"274","author":"M Takahashi","year":"1998","unstructured":"Takahashi M, Chesley A, Freyssenet D, Hood DA: Contractile activity-induced adaptations in the mitochondrial protein import system. Am J Physiol. 1998, 274: C1380-C1387.","journal-title":"Am J Physiol"},{"key":"489_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/092986609788167770","volume":"16","author":"CC Deocaris","year":"2009","unstructured":"Deocaris CC, Kaul SC, Wadhwa R: The versatile stress protein mortalin as a chaperone therapeutic agent. Protein Pept Lett. 2009, 16: 517-529.","journal-title":"Protein Pept Lett"},{"key":"489_CR48","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1158\/1078-0432.CCR-07-4181","volume":"14","author":"WM Hsu","year":"2008","unstructured":"Hsu WM, Lee H, Juan HF, Shih YY, Wang BJ, Pan CY, Jeng YM, Chang HH, Lu MY, Lin KH, Lai HS, Chen WJ, Tsay YG, Liao YF, Hsieh FJ: Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis. Clin Cancer Res. 2008, 14: 6237-6245.","journal-title":"Clin Cancer Res"},{"key":"489_CR49","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00702-009-0273-2","volume":"116","author":"L De Mena","year":"2009","unstructured":"De Mena L, Coto E, Sanchez-Ferrero E, Ribacoba R, Guisasola LM, Salvador C, Blazquez M, Alvarez V: Mutational screening of the mortalin gene (HSPA9) in Parkinson\u2019s disease. J Neural Transm. 2009, 116: 1289-1293.","journal-title":"J Neural Transm"},{"key":"489_CR50","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.neurobiolaging.2006.08.011","volume":"28","author":"C Osorio","year":"2007","unstructured":"Osorio C, Sullivan PM, He DN, Mace BE, Ervin JF, Strittmatter WJ, Alzate O: Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. Neurobiol Aging. 2007, 28: 1853-1862.","journal-title":"Neurobiol Aging"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/gm498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/gm498\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/gm498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:19:31Z","timestamp":1728382771000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/gm498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,18]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1186\/gm498","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,18]]},"assertion":[{"value":"21 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"95"}}